CorrespondenceGlobal multi-stakeholder endorsement of the MAFLD definition
References (11)
- et al.
A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement
J Hepatol
(2020) - et al.
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
Lancet Gastroenterol Hepatol
(2021) - et al.
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease
Lancet Gastroenterol Hepatol
(2021) - et al.
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa
Lancet Gastroenterol Hepatol
(2021) - et al.
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
Lancet Gastroenterol Hepatol
(2021)
There are more references available in the full text version of this article.
Cited by (140)
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
2024, European Journal of Internal MedicineActivation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation
2024, Cell Reports MedicineSteatotic liver disease, MASLD and risk of chronic kidney disease
2024, Diabetes and MetabolismPredictive modeling for the development of diabetes mellitus using key factors in various machine learning approaches
2024, Diabetes Epidemiology and ManagementHigh Variability on Alcohol Intake Threshold in Articles Using the MAFLD Acronym
2024, Gastro Hep Advances
- †
The list of signatories is in the appendix.
© 2022 Elsevier Ltd. All rights reserved.